Trump Administration Does Not Order Sufficient Pfizer/BioNTech COVID-19 Vaccine Jeopardizing Safety Of Americans

Trump And COVID-19 Vaccine

Pfizer/BioNTech vaccine is more than 90% effective against COVID-19. Many other researchers and scientists are working in various institutions to produce effective and safe treatment for coronavirus infection. 

The coronavirus pandemic can only end if everyone develops immunity against the virus either through active immunity or passive immunity. Another possibility of ending the pandemic is with the discovery of an effective treatment for coronavirus infection. 

Although Pfizer/BioNTech Coronavirus vaccine is effective, safe, and will receive FDA approval for emergency use, the Trump administration did not purchase enough vaccine doses that could be a problem for Americans.

ALSO READ: COVID-19 Second Wave Challenging The States, According To Last Week’s Reports

Trump Administration Decision Regarding Pfizer/BioNTech COVID-19 Vaccine

Mr. Trump during his presidency decided not to purchase additional doses of the Pfizer vaccine for coronavirus. However, the Trump administration has a contract with the company to provide 100 million doses of Pfizer/BioNTech COVID-19 vaccine. These doses will enable only 50 million people to get shots.

As Pfizer/BioNTech receives orders for their COVID-19 vaccine from multiple countries across the globe. So, they will now not be able to provide any additional doses to Americans before summer. Due to high demand, the company cannot supply additional-doses until the summer, even if the U.S. government places an order now. 

Yet Donald Trump said on Tuesday that doses would not be an issue as the administration could force Pfizer to provide more doses. Furthermore, on Tuesday, Trump signed an order that prioritizes the shipment of the coronavirus vaccine to America.

But the impact of this order is unclear as the incoming Biden administration will be responsible for the distribution of the vaccine. 

What Does Pfizer Board Of Directors Have To Say?

Scott Gottlieb is a member of Pfizer’s board of directors. And a former Food and Drug Administration (FDA) Commissioner. The New York Times reported on the Trump administration’s decision about not ordering additional doses, and Scott Gottlieb confirmed the decision on Tuesday. 

According to Gottlieb, Pfizer has previously given multiple chances to the Trump administration. Specifically, to buy additional doses of the COVID-19 vaccine. The company made offers in the summer, as well as in November when the safety and efficacy profiles of clinical trials were made public. The reports from Phase 3 clinical trials were enough to support the effectiveness of the coronavirus vaccine. Still, the Trump administration turned down the company’s offers.

Pfizer and its partner BioNTech have offered the government to take up an additional 100 million option agreement, as per Gottlieb. However, the government rejected the offer and was potentially thinking that more than one vaccine would get authorization from FDA. According to Scott Gottlieb, the government, with this perspective, probably decides to purchase a highly effective COVID-19 vaccine from multiple companies.

ALSO READ: Joe Biden’s Advisor Suggests Fair Distribution of COVID-19 Vaccine Globally

Remarks Of Others On Government Decision

Moncef Slaoui is the chief science advisor at OWS. According to Slaoui, the administration is considering six different companies, not just Pfizer, for the coronavirus vaccine. Besides, accepting Pfizer’s offer in the summers would not have been reasonable. As, at that time, there was no evidence of the effectiveness and safety of the Pfizer/BioNTech COVID-19 vaccine.

Slaoui further adds that the government in the summers has no idea which vaccine will be more effective with minimum side effects. Furthermore, the government wants what is best for the public. Moreover, without knowing about which vaccine is better than the others, and spending money on vaccination will be inappropriate. 

So far, the most promising vaccines have been from just two companies, Moderna and Pfizer. The government wishes to consider the formulations of other companies and choose the best option available. If other companies can produce coronavirus vaccine equivalent to the quality of Pfizer and Moderna, or even better than that, getting enough doses will not be a problem. 

However, if only Pfizer gets FDA approval, then getting sufficient doses can become a problem. 


Adeena Tariq Lari
The author is a graduate of dental surgery from the Dow University Health Sciences, Karachi. She has an academic background in content writing as well as English literature, giving her an edge in the field. Adeena is always curious about physical and mental health. She is always passionate about research and delivering high-quality reliable content to users.